SCHEMBL24374810

SCHEMBL24374810

C[C@H]1CN(C2COC2)C(=O)N1c1ccc(N)nc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CHRNB2 P17787 1/20 0.40
CHRNA4 P43681 1/20 0.40
MTOR P42345 9/20 0.38
PIK3R1 P27986 6/20 0.38
PIK3CA P42336 6/20 0.38
RICTOR Q6R327 6/20 0.38
RPTOR Q8N122 6/20 0.38
MAPKAP1 Q9BPZ7 6/20 0.38
MLST8 Q9BVC4 6/20 0.38
PIK3CD O00329 1/20 0.38
PIK3CB P42338 1/20 0.38
PIK3CG P48736 1/20 0.38
PIK3C3 Q8NEB9 1/20 0.38
DRD2 P14416 4/20 0.36
DRD3 P35462 4/20 0.36
DRD4 P21917 1/20 0.36
BTK Q06187 1/20 0.36
CHEK1 O14757 1/20 0.33
ATR Q13535 1/20 0.33
PDCD1 Q15116 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30116128 0.77 CHRNB2 (0.44) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL15713541 0.76 HDAC6 (0.39) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL19897368 0.73 CHRNB2 (0.43) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL17651735 0.73 CHRNB2 (0.43) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL17108489 0.72 MTOR (0.44) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL17108491 0.72 MTOR (0.44) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL30316567 0.72 MTOR (0.44) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL30315969 0.72 MTOR (0.44) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL14916061 0.72 CHRNB2 (0.43) CHRNB2CHRNA4MTORPIK3R1PIK3CA
SCHEMBL17796315 0.69 MTOR (0.46) CHRNB2CHRNA4MTORPIK3R1PIK3CA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230043030-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2023-02-09 US disclosed
US-11478474-B2 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor HUTCHISON MEDIPHARMA LIMITED (CN) 2022-10-25 US disclosed
US-20220125785-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF HUTCHISON MEDIPHARMA LIMITED (CN) 2022-04-28 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220125785-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF CYP3A4, CYP4B1, CYP3A5 CHRNB2 3221/4885CHRNA4 949/4885MTOR 2836/4885
US-11478474-B2 2-(3′-(hydroxymethyl)-1-methyl-5-((5-(2-methyl-4-(oxetan-3-yl)piperazin-1-yl)pyridin-2-yl)amino)-6-oxo-1,6-dihydro-[3,4′-bipyridin]-2′-yl)-7,7-dimethyl-7,8-dihydro-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one as a BTK inhibitor BTK, SYK, LCK CHRNB2 4213/4885CHRNA4 4455/4885MTOR 128/4885
US-20230043030-A1 HETEROARYL HETEROCYCLIC COMPOUNDS AND USES THEREOF CYP3A43, CYP3A5, CYP11B2 CHRNB2 2855/4885CHRNA4 3481/4885MTOR 2222/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.